#United States #New York #Securities #Faruqi & Faruqi #Altimmune

Investigative Actions by Faruqi & Faruqi on Altimmune

Faruqi & Faruqi, LLP, a prominent national law firm specializing in securities litigation, is currently looking into claims surrounding Altimmune, Inc., particularly focusing on financial losses experienced by its investors. This investigation is notably critical as the October 6, 2025 deadline approaches for those who suffered losses after purchasing or acquiring Altimmune's securities between August 10, 2023, and June 25, 2025.

On June 26, 2025, Altimmune released disheartening results related to its IMPACT Phase 2b trial of Pemvidutide, which was intended for the treatment of Metabolic Associated Steatohepatitis (MASH). Notably, while the company had previously communicated high expectations regarding the trial outcomes, the results revealed a lack of statistical significance in the primary endpoint concerning fibrosis reduction. Market analysts had anticipated a more favorable outcome, yet these results were attributed to an unexpectedly high placebo response.

The aftermath of this announcement caused Altimmune's stock to plummet dramatically, dropping from $7.71 per share at market close on June 25, 2025, to a staggering $3.61 per share by the following day—a significant loss of 53.2% in a single trading session. This event has prompted Faruqi & Faruqi to reach out to affected investors, encouraging them to discuss their legal rights regarding potential claims.

James (Josh) Wilson, a key partner at Faruqi & Faruqi, is spearheading this investigation. He invites any investors who sustained losses to connect with him directly at either 877-247-4292 or 212-983-9330 (Ext. 1310). Besides seeking investors, the firm is on the lookout for anyone possessing information regarding Altimmune’s operations, from whistleblowers to former employees, to better understand the situation and assist clients effectively.

The legal proceedings aim to establish a lead plaintiff, who will represent the group of investors during potential litigation against Altimmune. This individual would be the one with the most significant financial interest in the case while also mirroring the experience of other investors in the class.

Faruqi & Faruqi emphasizes that the decision to serve as lead plaintiff or remain a passive class member does not affect an individual’s ability to share in any recovery that may arise from the litigation. They assure that all communications will be treated confidentially, focusing on a thorough investigation leading to possible compensation for investors.

In conclusion, as the deadline looms, potential plaintiffs are encouraged to act quickly. The firm’s diligent work aims to protect investors’ rights and create a pathway for appropriate redress following these significant market changes affecting Altimmune. Updates on the situation can be tracked through Faruqi & Faruqi’s official channels, including their website and various social media platforms. Investors are advised to stay informed as developments unfold.